⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

February 19, 2024CureusOpen Access

Effectiveness of Ceftazidime-Avibactam in Gram-Negative Nosocomial Pneumonia: A Real-World Study in India

Neha Gupta Sanjith Saseedharan Yashesh Paliwal

View Full Paper

Ask AI

Bookmark

Share

Abstract

The incidences of nosocomial pneumonia in intensive care units (ICUs) in India have been reported to range from 9% to 58% and are associated with a mortality rate of 30-70%. Ceftazidime-avibactam has activity against OXA-48-like carbapenem-resistant

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Gupta et al. (2024) studied this question.

synapsesocial.com/papers/68e78961b6db6435876fbcfb https://doi.org/10.7759/cureus.54443

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Real-world Evidence on Use of Ceftazidime-Avibactam in the Management of Gram-Negative Infections: A Retrospective Analysis2024
2Real-World Evidence on Use of Ceftazidime-Avibactam in the Management of Gram-Negative Infections: A Retrospective Analysis2024 · 5 citations
3Investigation on the use of ceftazidime-avibactam at a national hospital in VietnamCross-Sectional Study · 2026
4Effectiveness and Outcomes of Ceftazidime -Avibactam in the Treatment of Infections due to Carbapenem-Resistant Klebsiella Pneumoniae.2024
5P-1323. Ceftazidime–avibactam in real-world clinical practice: results from a single centerOriginal Research · 2026